{"id":3787,"date":"2023-11-21T16:31:55","date_gmt":"2023-11-21T05:31:55","guid":{"rendered":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/naltrexone-a-useful-addendum-to-alcohol-use-disorder-therapy-pharmacotherapy-for-alcohol-use-disorder-a-systematic-review-and-meta-analysis\/"},"modified":"2025-11-26T20:17:50","modified_gmt":"2025-11-26T09:17:50","slug":"naltrexone-a-useful-addendum-to-alcohol-use-disorder-therapy-pharmacotherapy-for-alcohol-use-disorder-a-systematic-review-and-meta-analysis","status":"publish","type":"post","link":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/naltrexone-a-useful-addendum-to-alcohol-use-disorder-therapy-pharmacotherapy-for-alcohol-use-disorder-a-systematic-review-and-meta-analysis\/","title":{"rendered":"Naltrexone, a Useful Addendum to Alcohol Use Disorder Therapy Pharmacotherapy for Alcohol Use Disorder A Systematic Review and Meta-Analysis"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3787\" class=\"elementor elementor-3787\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4ff109f e-flex e-con-boxed e-con e-parent\" data-id=\"4ff109f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2e81a253 elementor-widget elementor-widget-text-editor\" data-id=\"2e81a253\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><strong><em>Key Points<\/em><\/strong><\/p><p><strong>Question<\/strong>: Which pharmacotherapies are associated with improved outcomes for people with alcohol use disorder?<\/p><p><strong>Findings<\/strong>:\u00a0In this systematic review and meta-analysis that included 118 clinical trials and 20\u202f976 participants, 50 mg\/d of oral naltrexone and acamprosate were each associated with significantly improved alcohol consumption-related outcomes compared with placebo.<\/p><p><strong>Meaning:<\/strong>\u00a0\u00a0These findings support oral naltrexone at 50 mg\/d and acamprosate as first-line therapies for alcohol use disorder.<\/p><p><strong><em>Abstract<\/em><\/strong><\/p><p><strong>Objective<\/strong>:\u00a0To compare efficacy and comparative efficacy of therapies for alcohol use disorder.<\/p><p><strong>Study Selection<\/strong>:\u00a0For efficacy outcomes, randomized clinical trials of at least 12 weeks\u2019 duration were included. For adverse effects, randomized clinical trials and prospective cohort studies that compared drug therapies and reported health outcomes or harms were included.<\/p><p><strong>Main Outcomes and Measures<\/strong>:\u00a0The primary outcome was alcohol consumption. Secondary outcomes were motor vehicle crashes, injuries, quality of life, function, mortality, and harms.<\/p><p><strong>Conclusions and Relevance:<\/strong>\u00a0\u00a0In conjunction with psychosocial interventions, these findings support the use of oral naltrexone at 50 mg\/d and acamprosate as first-line pharmacotherapies for alcohol use<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-af2bf54 elementor-widget elementor-widget-ucaddon_icon_pointer_button\" data-id=\"af2bf54\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"ucaddon_icon_pointer_button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\n<!-- start Icon Pointer Button -->\n\t\t<link id='font-awesome-css' href='https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/plugins\/unlimited-elements-for-elementor-premium\/assets_libraries\/font-awesome6\/fontawesome-all.min.css' type='text\/css' rel='stylesheet' >\n\t\t<link id='font-awesome-4-shim-css' href='https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/plugins\/unlimited-elements-for-elementor-premium\/assets_libraries\/font-awesome6\/fontawesome-v4-shims.min.css' type='text\/css' rel='stylesheet' >\n\n<style>\/* widget: Icon Pointer Button *\/\n\n#uc_icon_pointer_button_elementor_af2bf54 *{\n\tmargin:0;\n\tbox-sizing: border-box;\n}\n\n#uc_icon_pointer_button_elementor_af2bf54 {\n  text-align:left;\n  direction: ltr;\n}\n\n#uc_icon_pointer_button_elementor_af2bf54 .icon_pointer_button_holder\n{\n  display:inline-block;\n}\n\n#uc_icon_pointer_button_elementor_af2bf54 a {\n\tdisplay: flex;\n\tposition: relative;\n\ttransition: all 0.3s;\n    text-decoration:none;\n    overflow:hidden;\n}\n\n#uc_icon_pointer_button_elementor_af2bf54 .icon_pointer_button_icon\n{\n  display:flex;\n  align-items:center;\n  justify-content:center;\n  position:relative;\n  transition: all 0.3s;\n}\n\n#uc_icon_pointer_button_elementor_af2bf54 .icon_pointer_button_text\n{\n  flex-grow: 1;\n  text-align:center;\n}\n\n\n\t\n#uc_icon_pointer_button_elementor_af2bf54 .icon_pointer_button_icon::after {\n\tcontent: \"\";\n    top: 50%;\n    clip-path: polygon(100% 50%, 0 0, 0 100%);\n  \ttransition: all 0.3s;\n  \tposition:absolute;\t\n      \tright: 0px;\t\n    transform: translateX(98%) translateY(-50%);\n  \t\t\n}  \n\n#uc_icon_pointer_button_elementor_af2bf54 .icon_pointer_button_icon_holder\n{\n  transition: all 0.3s;\n  display:block;\n  line-height:1em;\n  background-color:transparent;\n\n}\n\n<\/style>\n\n<div class=\"icon_pointer_button\" id=\"uc_icon_pointer_button_elementor_af2bf54\">\n  \t<div class=\"icon_pointer_button_holder\">\n    <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2811435?guestAccessKey=78839cc1-06fe-422c-bd49-c1b7b266519b&amp;#038;utm_source=silverchair&amp;#038;utm_medium=email&amp;#038;utm_campaign=jama_network&amp;#038;utm_content=network_highlights&amp;#038;utm_term=111823&amp;#038;adv=000004445130\" class=\"ue-icon-btn\"  target='_blank'>\n       <span class=\"icon_pointer_button_icon\">\n         <span class=\"icon_pointer_button_icon_holder\"><i class=\"far fa-arrow-alt-circle-right\" aria-hidden=\"true\"><\/i><\/span>\n       <\/span>\n       <span class=\"icon_pointer_button_space\"><\/span>\n       <span class=\"icon_pointer_button_text\">For Complwete Research<\/span>          \n    <\/a>\n    <\/div>\n<\/div>\n<!-- end Icon Pointer Button -->\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Key Points Question: Which pharmacotherapies are associated with improved outcomes for people with alcohol use disorder? Findings:\u00a0In this systematic review and meta-analysis that included 118 clinical trials and 20\u202f976 participants, 50 mg\/d of oral naltrexone and acamprosate were each associated with significantly improved alcohol consumption-related outcomes compared with placebo. Meaning:\u00a0\u00a0These findings support oral naltrexone at [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":"","_wp_rev_ctl_limit":""},"categories":[23],"tags":[],"class_list":["post-3787","post","type-post","status-publish","format-standard","hentry","category-naltrexone"],"_links":{"self":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/3787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/comments?post=3787"}],"version-history":[{"count":1,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/3787\/revisions"}],"predecessor-version":[{"id":9931,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/3787\/revisions\/9931"}],"wp:attachment":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/media?parent=3787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/categories?post=3787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/tags?post=3787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}